| Autor: |
Schacht JP; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA., Voronin KE; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA., Randall PK; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA., Anton RF; Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, SC, USA. |
| Jazyk: |
angličtina |
| Zdroj: |
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology [Neuropsychopharmacology] 2018 May; Vol. 43 (6), pp. 1247-1256. Date of Electronic Publication: 2017 Dec 06. |
| DOI: |
10.1038/npp.2017.298 |
| Abstrakt: |
Dopamine (DA) signaling regulates many aspects of Alcohol Use Disorder (AUD). However, clinical studies of dopaminergic medications, including the DA partial agonist aripiprazole (APZ), have been inconsistent, suggesting the possibility of a pharmacogenetic interaction. This study examined whether variation in DA-related genes moderated APZ effects on reward-related AUD phenotypes. The interacting effects of APZ and a variable number tandem repeat (VNTR) polymorphism in DAT1/SLC6A3 (the gene encoding the DA transporter (DAT)) were tested. In addition, interactions between APZ and a genetic composite comprising the DAT1 VNTR and functional polymorphisms in catechol-O-methyltransferase (COMT), DRD2, and DRD4 were evaluated. Ninety-four non-treatment-seeking individuals with AUD were genotyped for these polymorphisms, randomized to APZ (titrated to 15 mg) or placebo for 8 days, and underwent an fMRI alcohol cue-reactivity task (day 7; n=81) and a bar lab paradigm (day 8). Primary outcomes were alcohol cue-elicited ventral striatal (VS) activation and the number of drinks consumed in the bar lab. DAT1 genotype significantly moderated medication effects, such that APZ, relative to placebo, reduced VS activation and bar-lab drinking only among carriers of the DAT1 9-repeat allele, previously associated with lower DAT expression and greater reward-related brain activation. The genetic composite further moderated medication effects, such that APZ reduced the primary outcomes more among individuals who carried a larger number of DAT1, COMT, DRD2, and DRD4 alleles associated with higher DA tone. Taken together, these data suggest that APZ may be a promising AUD treatment for individuals with a genetic predisposition to higher synaptic DA tone. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
Full text from SpringerLink